M
Michael D. Hocker
Researcher at Ambit Biosciences
Publications - 8
Citations - 1699
Michael D. Hocker is an academic researcher from Ambit Biosciences. The author has contributed to research in topics: Receptor tyrosine kinase & Gene. The author has an hindex of 3, co-authored 6 publications receiving 1337 citations.
Papers
More filters
Journal ArticleDOI
Comprehensive analysis of kinase inhibitor selectivity.
Mindy I. Davis,Jeremy P Hunt,Jeremy P Hunt,Sanna Herrgard,Pietro Ciceri,Pietro Ciceri,Lisa M Wodicka,Lisa M Wodicka,Gabriel Pallares,Gabriel Pallares,Michael D. Hocker,Daniel K Treiber,Daniel K Treiber,Patrick P Zarrinkar,Patrick P Zarrinkar +14 more
TL;DR: Analysis of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.
Patent
Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
TL;DR: In this article, heterocyclic compounds for treatment of CSFIR, FLT3, KIT, and/or PDGFRβ kinase mediated diseases are presented. But the methods of using the compounds and compositions are not described.
Proceedings ArticleDOI
Abstract 903: AC708 is a potent and selective inhibitor of CSF1R and reduces tumor associated macrophage infiltration in a breast tumor model .
Robert C. Armstrong,Barbara Belli,Martin W. Rowbottom,Ron R. Nepomuceno,Alan Q. Dao,Allison M. Rooks,Dan Brigham,Craig McMannus,Michael D. Hocker,Mark W. Holladay,Gang Liu +10 more
TL;DR: It is demonstrated that AC708 possesses significant specificity for CSF1R relative to the rest of the kinome, and to the closely relatedPDGFR family receptors PDGFRα and β, FLT3, and KIT, and support the development of AC708 as a therapeutic in oncology.
Patent
Heterocyclic compounds and methods of use thereof
TL;DR: In this paper, heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases are presented.
Journal ArticleDOI
Discovery of novel small molecules that recruit DCAF11 for selective degradation of BRD4
Greg S. Parker,J. Toth,Geoffray Leriche,Sarah Fish,Aleks Jamborcic,Gabrielle A. Blanco,Elizabeth Daniele,Kenneth Steadman,X Li,L. Yang,Stephen Chien,Alejandro R. Dearie,Kenneth Chng,Erika Green,Michael D. Hocker,Ye Zhang,Phil Thompson,S. Bailey +17 more
TL;DR: In this article , an E3 ligase agnostic chemical library was screened using an ultra-high throughput cell-based screening (uHTS) platform, which resulted in identification of selective monovalent degraders that target the bromodomain extra-terminal (BET) protein, BRD4.